search
Back to results

The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis

Primary Purpose

Necrotizing Enterocolitis, Death

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
probiotics
glucose solution
Sponsored by
Shenzhen Bao'an Maternal and Child Health Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Necrotizing Enterocolitis focused on measuring probiotics, preterm very low birth weight infants, necrotizing enterocolitis, gut microflora, TLR, NF-KB, inflammatory factors

Eligibility Criteria

undefined - 3 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Preterm infants ≦ 34 weeks gestational age and birth weight below 1500 gm and who survive to NICU are eligible for the trial.

Exclusion Criteria:

  • severe asphyxia (stage III),
  • fetal chromosomal anomalies,
  • cyanotic congenital heart disease,
  • congenital intestinal atresia, gastroschisis, omphalocele, active upper gastric intestinal bleeding,
  • lacking/refused of parental consent,
  • those who are fasted for >3 weeks during the study period.

Sites / Locations

  • Longhua People's Hospital of Shenzhen
  • Shenzhen Bao'an Maternal and Child Health HospitalRecruiting
  • Shenzhen People's HospitalRecruiting
  • Shenzhen Sixth People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

probiotics group

control group

Arm Description

Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.

control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.

Outcomes

Primary Outcome Measures

the incidence of combined death and necrotizing enterocolitis

Secondary Outcome Measures

the incidence of sepsis,intraventricular hemorrhage(IVH)(grade 3-4),feeding intolerance(FI),bronchopulmonary dysplasia(BPD),parenteral nutrition associated liver disease(PNALD)and retinopathyof prematurity(ROP).

Full Information

First Posted
September 12, 2015
Last Updated
March 26, 2016
Sponsor
Shenzhen Bao'an Maternal and Child Health Hospital
Collaborators
China Medical University Hospital, Shenzhen People's Hospital, Shenzhen Sixth People's Hospital, Longhua Hospital Of Baoan District, Shenzhen
search

1. Study Identification

Unique Protocol Identification Number
NCT02552706
Brief Title
The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis
Official Title
The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Unknown status
Study Start Date
September 2014 (undefined)
Primary Completion Date
January 2017 (Anticipated)
Study Completion Date
September 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shenzhen Bao'an Maternal and Child Health Hospital
Collaborators
China Medical University Hospital, Shenzhen People's Hospital, Shenzhen Sixth People's Hospital, Longhua Hospital Of Baoan District, Shenzhen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight infants.
Detailed Description
Necrotizing enterocolitis (NEC) remains the most catastrophic gastrointestinal emergencies in preterm very low birth weight (VLBW) infants.Although study showed it is a multifactorial disease, its pathogenesis is still not yet unclear currently. Prematurity and formula feeding is considered as the main risk factors.Gut microbiota disturbance and immature immune system is associated with NEC. A lot of studies had showed that oral probiotics can alter gut microbiota flora colonization and reduce the incidence of NEC,but the exact mechanism remains unclear.The aim of this study is to elucidate the clinical efficacy and possible molecular mechanism of oral mixture probiotics in preventing NEC among preterm VLBW infants. Patient Registry procedures: First,randomized numbers was generated by the computer and sent to the principal investigator(PI) at each center when an infant was eligible for enrollment.Second, patient will be assigned randomly to experimental group or control group by PI.Finally,the PI at each center will be responsible for the accuracy,completeness or representativeness of medical records, registry forms,data collection. Sample size determination: The incidence of death and NEC was around 20% recently.To reduce the incidence of NEC and death to 10% at discharge would require a 50% improvement.At 80% power at P = 0.05 (two-sided),the loss rate of 0.2, this would require 135 subjects per arm. Statistical analysis:The two groups were compared by a Χ2-test for categorical variables,Mann-Whitney U Test were used when reporting medians.A P value of <0.05 was considered statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Necrotizing Enterocolitis, Death
Keywords
probiotics, preterm very low birth weight infants, necrotizing enterocolitis, gut microflora, TLR, NF-KB, inflammatory factors

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
270 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
probiotics group
Arm Type
Experimental
Arm Description
Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
Arm Title
control group
Arm Type
Placebo Comparator
Arm Description
control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
Intervention Type
Dietary Supplement
Intervention Name(s)
probiotics
Intervention Description
Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
Intervention Type
Dietary Supplement
Intervention Name(s)
glucose solution
Intervention Description
Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
Primary Outcome Measure Information:
Title
the incidence of combined death and necrotizing enterocolitis
Time Frame
at 36 weeks correct gestational age
Secondary Outcome Measure Information:
Title
the incidence of sepsis,intraventricular hemorrhage(IVH)(grade 3-4),feeding intolerance(FI),bronchopulmonary dysplasia(BPD),parenteral nutrition associated liver disease(PNALD)and retinopathyof prematurity(ROP).
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 8 weeks
Other Pre-specified Outcome Measures:
Title
the influence of oral probiotics on gut microbiota and immunomodulatory
Description
test fecal microbiota via high throughput sequencing and blood toll like receptor(TLR)2,TLR4,neclear factor kappa B(NF-KB)were detected using flow cytomtry.Inflammatory factors of blood were tested via Cytometric Bead Array(CBA).All above samples were obtained only from Shenzhen Bao'an Maternal and Child Health Hospital.The fecal DNA were first extracted at centre laboratory in aboved hospital and sent them to Beijing Genomics Institute(BGI) for further sequenceing ,if necessary, quantitative polymerase chain reaction(qPCR)of gut dominant bacterias related to late onset sepsis(LOS) will be tested for assessing the effect of oral probiotics on gut microbiota and underlying the mechanism. Flow cytometry analysis of TLR2,TLR4 and NF-KB were made by the senior laboratorian of our department and resposible for the accuracy of experimental result. CBA of inflammatory factors will be made by senting the blood samples to Beijing JIAMAY BIOLAB.
Time Frame
at birth, 2 and 4 weeks of life, 36 week correct gestational age.

10. Eligibility

Sex
All
Maximum Age & Unit of Time
3 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Preterm infants ≦ 34 weeks gestational age and birth weight below 1500 gm and who survive to NICU are eligible for the trial. Exclusion Criteria: severe asphyxia (stage III), fetal chromosomal anomalies, cyanotic congenital heart disease, congenital intestinal atresia, gastroschisis, omphalocele, active upper gastric intestinal bleeding, lacking/refused of parental consent, those who are fasted for >3 weeks during the study period.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yuefeng Li, M.D.
Phone
86+13751029103
Email
liyuefeng111@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yuefeng Li, M.D.
Organizational Affiliation
Shenzhen Bao'an Maternal and Child Health Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
HungChih Lin, M.D.
Organizational Affiliation
China Medical University Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Benqing Wu, M.D.
Organizational Affiliation
Shenzhen People's Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Xiaodong Li, M.D.
Organizational Affiliation
Shenzhen Sixth People's Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Zhangxin Wang, M.D.
Organizational Affiliation
Longhua Hospital Of Baoan District, Shenzhen
Official's Role
Study Director
Facility Information:
Facility Name
Longhua People's Hospital of Shenzhen
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518100
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Shenzhen Bao'an Maternal and Child Health Hospital
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518100
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuefeng Li, M.D.
Phone
+86-13751029103
Email
liyuefeng111@sina.com
Facility Name
Shenzhen People's Hospital
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518100
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benqing Wu, M.D.
Phone
+86-13902436593
Email
wubenqing783@126.com
Facility Name
Shenzhen Sixth People's Hospital
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518100
Country
China
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
18829790
Citation
Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, Tsao LY, Chen CH, Su BH. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008 Oct;122(4):693-700. doi: 10.1542/peds.2007-3007.
Results Reference
background
PubMed Identifier
16521683
Citation
Genzel-Boroviczeny O, MacWilliams S, Von Poblotzki M, Zoppelli L. Mortality and major morbidity in premature infants less than 31 weeks gestational age in the decade after introduction of surfactant. Acta Obstet Gynecol Scand. 2006;85(1):68-73. doi: 10.1080/00016340500290947.
Results Reference
result
PubMed Identifier
22682464
Citation
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012 Jun 9;379(9832):2162-72. doi: 10.1016/S0140-6736(12)60820-4.
Results Reference
result
PubMed Identifier
16984980
Citation
Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2007 May;92(3):F193-8. doi: 10.1136/adc.2006.099929. Epub 2006 Sep 19.
Results Reference
result
PubMed Identifier
24525171
Citation
Huda S, Chaudhery S, Ibrahim H, Pramanik A. Neonatal necrotizing enterocolitis: Clinical challenges, pathophysiology and management. Pathophysiology. 2014 Feb;21(1):3-12. doi: 10.1016/j.pathophys.2013.11.009. Epub 2014 Feb 11.
Results Reference
result
PubMed Identifier
24314171
Citation
Hall NJ, Eaton S, Pierro A. Royal Australasia of Surgeons Guest Lecture. Necrotizing enterocolitis: prevention, treatment, and outcome. J Pediatr Surg. 2013 Dec;48(12):2359-67. doi: 10.1016/j.jpedsurg.2013.08.006.
Results Reference
result
PubMed Identifier
17943776
Citation
Quigley MA, Henderson G, Anthony MY, McGuire W. Formula milk versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002971. doi: 10.1002/14651858.CD002971.pub2.
Results Reference
result
PubMed Identifier
19019028
Citation
Mshvildadze M, Neu J, Mai V. Intestinal microbiota development in the premature neonate: establishment of a lasting commensal relationship? Nutr Rev. 2008 Nov;66(11):658-63. doi: 10.1111/j.1753-4887.2008.00119.x.
Results Reference
result
PubMed Identifier
17336180
Citation
Sharma R, Tepas JJ 3rd, Hudak ML, Mollitt DL, Wludyka PS, Teng RJ, Premachandra BR. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg. 2007 Mar;42(3):454-61. doi: 10.1016/j.jpedsurg.2006.10.038.
Results Reference
result
PubMed Identifier
23401695
Citation
Nair V, Soraisham AS. Probiotics and prebiotics: role in prevention of nosocomial sepsis in preterm infants. Int J Pediatr. 2013;2013:874726. doi: 10.1155/2013/874726. Epub 2013 Jan 14.
Results Reference
result
PubMed Identifier
24285463
Citation
Sarowska J, Choroszy-Krol I, Regulska-Ilow B, Frej-Madrzak M, Jama-Kmiecik A. The therapeutic effect of probiotic bacteria on gastrointestinal diseases. Adv Clin Exp Med. 2013 Sep-Oct;22(5):759-66.
Results Reference
result
PubMed Identifier
24287935
Citation
Di Gioia D, Aloisio I, Mazzola G, Biavati B. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants. Appl Microbiol Biotechnol. 2014 Jan;98(2):563-77. doi: 10.1007/s00253-013-5405-9. Epub 2013 Nov 28.
Results Reference
result
PubMed Identifier
22207578
Citation
Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kappaB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15;302(6):G608-17. doi: 10.1152/ajpgi.00266.2011. Epub 2011 Dec 29.
Results Reference
result
PubMed Identifier
20403939
Citation
Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010 May;125(5):921-30. doi: 10.1542/peds.2009-1301. Epub 2010 Apr 19.
Results Reference
result
PubMed Identifier
24365655
Citation
Lu P, Sodhi CP, Hackam DJ. Toll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis. Pathophysiology. 2014 Feb;21(1):81-93. doi: 10.1016/j.pathophys.2013.11.007. Epub 2013 Dec 22.
Results Reference
result
PubMed Identifier
23762089
Citation
Hackam DJ, Afrazi A, Good M, Sodhi CP. Innate immune signaling in the pathogenesis of necrotizing enterocolitis. Clin Dev Immunol. 2013;2013:475415. doi: 10.1155/2013/475415. Epub 2013 May 23.
Results Reference
result
PubMed Identifier
23139215
Citation
Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol. 2013 Jan 15;304(2):G132-41. doi: 10.1152/ajpgi.00142.2012. Epub 2012 Nov 8.
Results Reference
result
PubMed Identifier
33058137
Citation
Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database Syst Rev. 2020 Oct 15;10(10):CD005496. doi: 10.1002/14651858.CD005496.pub5.
Results Reference
derived

Learn more about this trial

The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis

We'll reach out to this number within 24 hrs